We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
19 July 2017
As previously reported, on May 16 2017 Minister of Health Jane Philpott announced a consultation regarding proposed amendments to the Patented Medicines Regulations that would significantly affect the Patented Medicines Prices Review Board's (PMPRB's) approach to drug price evaluation.
Key proposed changes include:
The consultation period is open until June 28 2017.(1) Based on remarks provided by Philpott to the Economic Club of Canada, the proposed regulatory amendments are expected to be published in Autumn 2017 in Part I of the Canada Gazette for further feedback, with ultimate implementation no later than the end of 2018.
The vice chair of the PMPRB issued a statement welcoming the actions to "strengthen and modernize [the PMPRB's] pricing framework to reduce the cost of prescription drugs".
On April 11 2017 the PMPRB published the first edition of Meds Entry Watch, a new annual publication that provides information on recently launched drugs in Canada and select international markets. The inaugural edition provides an analysis of Canadian and select international markets for 2009-2014 and a preliminary analysis of drugs launched in 2015.
On May 24 2017 the PMPRB released the third edition of CompassRx, an annual report published under the National Prescription Drug Utilisation Information System research initiative. CompassRx provides insight into drivers of drug expenditures in select Canadian public drug plans. The key findings of the report include:
For further information on this topic please contact Daphne Lainson at Smart & Biggar/Fetherstonhaugh by telephone (+1 613 232 2486) or email (firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) The consultation document can be found here.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.